PATENT – FARMASÖTİK PATENT ÇEŞİTLERİ

Prof. Dr. Yıldız ÖZSOY

KİMLER PATENT/FM BAŞVURUSU YAPABİLİR ?

(Patent KHK Madde 2)

- TC vatandaşları
- Türkiye'de ikamet eden kişiler
- Türkiye'de sınai veya ticari faaliyette bulunan kişiler
- Paris Sözleşmesi veya DTÖ Anlaşmasına taraf ülke vatandaşları
- Karşılıklılık ilkesi kapsamında Türk vatandaşlarına Patent koruması hakkı tanıyan ülke vatandaşları

BULUŞ NİTELİĞİNDE OLMADİKLARİ İÇİN PATENT VERİLMEYECEK KONULAR (PATENT KHK MADDE 6)

a - Keşifler, bilimsel teoriler, matematik metotları;

b - Zihni, ticari ve oyun faaliyetlerine ilişkin plan, usul ve kurallar;

c - Edebiyat ve sanat eserleri, bilim eserleri, estetik niteliği olan yaratmalar, bilgisayar yazılımları;

d - Bilginin derlenmesi, düzenlenmesi, sunulması ve iletilmesi ile ilgili teknik yönü bulunmayan usuller.

BULUŞ NİTELİĞİNDE OLMADİKLARİ İÇİN PATENT VERİLMEYECEK KONULAR (PATENT KHK MADDE 6)

e- İnsan veya hayvan vücuduna uygulanacak cerrahi ve tedavi usulleri ile insan, hayvan vücudu ile ilgili teşhis usulleri. (Bu hüküm, bu usullerin herhangi birinde kullanılan terkip ve maddeler ile bunların üretim usullerine uygulanmaz.)

BULUŞ NİTELİĞİNDE OLMALARİNA RAĞMEN PATENT VERİLMEYECEK BULUŞLAR (PATENT KHK MADDE 6)

f- Konusu kamu düzenine veya genel ahlaka aykırı olan buluşlar.

g - Bitki veya hayvan türleri veya önemli ölçüde biyolojik esaslara dayanan bitki veya hayvan yetiştirilmesi usulleri.

FARMASÖTİK PATENT ÇEŞİTLERİ

MOLEKÜL PATENTİ ÖRNEĞİ

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 240 228**
B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication of the patent specification: **07.11.90**

(51) Int. Cl.[5]: **C07D 281/16**, A61K 31/55 // C07C323/62

(21) Application number: **87302539.9**

(22) Date of filing: **24.03.87**

Claims for the Contracting States: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A compound of formula II:



II

or a salt thereof.

Polimorf Patent Örneği

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 September 2004 (16.09.2004)

PCT

(10) International Publication Number
WO 2004/078735 A1

(51) International Patent Classification[7]: **C07D 281/16**, A61K 31/55

(21) International Application Number: PCT/IN2003/000043

(22) International Filing Date: 3 March 2003 (03.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant *(for all designated States except US)*: **HETERO**

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

We claim:

1) Quetiapine fumarate crystalline Form I characterized by x-ray powder diffractogram having peaks expressed as 2θ at about 7.3, 9.2, 11.6, 13.3, 14.4, 14.8, 15.3, 15.9, 16.2, 16.7, 17.6, 19.1, 19.7, 20.1, 20.8, 21.1, 21.8, 22.3, 23.4, 24.3, 24.7, 25.1, 25.6, 27.1, 28.5, 29.5, 33.2, 40.4 deg.

DOZAJ FORM İLE İLGİLİ PATENT ÖRNEĞİ

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/034921 A1

(51) International Patent Classification[7]: A61K 9/20

(21) International Application Number:
PCT/US2004/032902

(22) International Filing Date: 6 October 2004 (06.10.2004)

(74) Agent: ENDRES, Martin, P.; Hedman & Costigan, P.C., 1185 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

We claim:

1. A rapidly disintegrating oral pharmaceutical dosage formulation comprising:

a water insoluble or slightly water soluble neurological agent wherein the total weight of the tablet is less than 500 mg.

FORMÜLASYON PATENT ÖRNEĞİ

T.C.
(19) TÜRK PATENT[redacted]ENSTİTÜSÜ

(10) **TR 2001 01310 T2**

(12) **Patent Başvurusu**

(21) Başvuru No.
a 2001/01310

(22) Başvuru Tarihi
1999/10/29

(43) Başvuru Yayın Tarihi
2001/10/22

(51) Buluşun tasnif sınıf(lar)ı
A61K 31/4709
A61K 9/20
A61K 9/28
A61P 31/04

(86) Uluslararası Başvuru No
PCT/EP99/08230

(30) Rüçhan Bilgileri (32) (33) (31)
1998/11/10 DE 198 55 758,2

(74) Vekil
STOK SINAİ MÜLKİYET HİZMETLERİ A.Ş.
Büyükdere Caddesi No:173 A Blok Kat:11 80620
1.Levent-İSTANBUL

İSTEMLER

1. Oral uygulama için aşağıdakileri içeren bir farmasötik preparat olup moksifloksasin veya bunun bir tuzu ve/veya hidratı,
en az bir kuru birleştirici,
en az bir dağıtıcı, ve
en az bir kayganlaştırıcı,
özelliği preparatın %2.5 ila %25 laktoz içermesidir.

KOMBİNASYON PATENT ÖRNEĞİ

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 February 2007 (22.02.2007)

PCT

(10) International Publication Number
WO 2007/022113 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2006/031699

(22) International Filing Date: 15 August 2006 (15.08.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/709,083 17 August 2005 (17.08.2005) US

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every*

1. A solid dosage form of valsartan comprising:

valsartan;

amlodipine; and

pharmaceutically acceptable additives suitable for the preparation of solid dosage forms of valsartan.

ENDİKASYON PATENT ÖRNEĞİ

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 0 730 865 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
19.12.2001 Bulletin 2001/51

(51) Int Cl.7: **A61K 31/495**, A61K 31/505, A61K 31/40, A61K 31/445, A61K 31/44, A61P 25/28

(21) Application number: **96100360.5**

(22) Date of filing: **11.01.1996**

(54) **Use of serotonin and dopamine receptor blockers for the treatment of mental disorders associated with cerebrovascular disease**

Verwendung von Serotonin- und Dopaminrezeptorblockern zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen

Utilisation d'antagonistes de récepteurs de la sérotonine et de la dopamine pour le traitement de maladies mentales associés à les maladies cérébrovasculaires

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

(30) Priority: **12.01.1995 JP 319195**

(43) Date of publication of application:
11.09.1996 Bulletin 1996/37

(60) Divisional application:
01112981.4

- **DATABASE WPI Section Ch, Week 8646 Derwent Publications Ltd., London, GB; Class B02, AN 86-259579 XP002005787 & JP-A-61 221 186 (JANSSEN PHARM NV) , 1 October 1986**
- **DATABASE WPI Section Ch, Week 8904 Derwent Publications Ltd., London, GB; Class B02, AN 88-251872 XP002005788 & JP-A-63 301 861 (PFIZER INC) , 8 December 1988**
- **DATABASE WPI Section Ch, Week 9117 Derwent Publications Ltd., London, GB; Class B02, AN 90-377450 XP002005789 & JP-A-03 063 263**

Claims

1. Use of SM-9018 or Risperidone for the manufacture of a medicament for treating mental disorders resulting from cerebrovascular disorders.

SENTEZ-PROSES PATENT ÖRNEĞİ

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 1 980 552 A2

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:
15.10.2008 Bulletin 2008/42

(51) Int Cl.:
C07C 271/44 (2006.01)

(21) Application number: 08007105.3

(22) Date of filing: 10.04.2008

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:

• Vajrala, Venkata, Reddy
Hyderabad 500 072
Andhra Pradesh (IN)
• Varanasi, Ganesh
Hyderabad 500 060

Claims:

1. A process for preparing rivastigmine or a salt thereof comprising reacting S-(-)-[1-(3-hydroxyphenyl)ethyl]dimethylamine with N-ethyl-N-methyl carbamoyl chloride in the presence of an organic base to obtain a free base of rivastigmine.

11. A process for preparing 1- (3-methoxy-phenyl)-ethylamine comprising the steps of:

a) reacting 3-hydroxy acetophenone with dimethyl sulphate in the presence of potassium carbonate thereby obtaining 1-(3-methoxyphenyl)ethanone;

b) reacting 1-(3-methoxyphenyl)ethanone with a reagent which is a source of ammonia to afford an aminated intermediate; and

c) reacting the aminated intermediate with a reducing agent to afford 1- (3-methoxy-phenyl)-ethylamine.